|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kovacic P and Jacintho JD: Mechanisms of
carcinogenesis: focus on oxidative stress and electron transfer.
Curr Med Chem. 8:773–796. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodrigues NR, Rowan A, Smith ME, et al:
p53 mutations in colorectal cancer. Proc Natl Acad Sci USA.
87:7555–7559. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sablina AA, Budanov AV, Ilyinskaya GV,
Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function
of the p53 tumor suppressor. Nat Med. 11:1306–1313. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vousden KH and Ryan KM: p53 and
metabolism. Nat Rev Cancer. 9:691–700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Green DR and Kroemer G: Cytoplasmic
functions of the tumour suppressor p53. Nature. 458:1127–1130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Budanov AV and Karin M: p53 target genes
sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.
Cell. 134:451–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Budanov AV, Sablina AA, Feinstein E,
Koonin EV and Chumakov PM: Regeneration of peroxiredoxins by
p53-regulated sestrins, homologs of bacterial AhpD. Science.
304:596–600. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Velasco-Miguel S, Buckbinder L, Jean P, et
al: PA26, a novel target of the p53 tumor suppressor and member of
the GADD family of DNA damage and growth arrest inducible genes.
Oncogene. 18:127–137. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Budanov AV, Shoshani T, Faerman A, et al:
Identification of a novel stress-responsive gene Hi95 involved in
regulation of cell viability. Oncogene. 21:6017–6031. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 knockdown by RNA interference inhibits the
growth of colorectal cancer cells by downregulating Wnt/β-catenin
signaling. Cancer Lett. 343:190–199. 2014. View Article : Google Scholar
|
|
14
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 is upregulated in colorectal cancer and
contributes to colorectal cancer cells’ survival by protecting
cells from oxidative stress. Mol Cell Biochem. 387:261–270. 2014.
View Article : Google Scholar
|
|
15
|
Maiuri MC, Malik SA, Morselli E, et al:
Stimulation of autophagy by the p53 target gene Sestrin2. Cell
Cycle. 8:1571–1576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XY, Wu XQ, Deng R, Sun T, Feng GK
and Zhu XF: Upregulation of sestrin 2 expression via JNK pathway
activation contributes to autophagy induction in cancer cells. Cell
Signal. 25:150–158. 2013. View Article : Google Scholar
|
|
17
|
Wang N, Pan W, Zhu M, Zhang M, Hao X,
Liang G and Feng Y: Fangchinoline induces autophagic cell death via
p53/sentrin2/AMPK signaling in human hepatocellular carcinoma
cells. Br J Pharmacol. 164:731–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garber ME, Troyanskaya OG, Schluens K, et
al: Diversity of gene expression in adenocarcinoma of the lung.
Proc Natl Acad Sci USA. 98:13784–13789. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wachi S, Yoneda K and Wu R:
Interactome-transcriptome analysis reveals the high centrality of
genes differentially expressed in lung cancer tissues.
Bioinformatics. 21:4205–4208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su LJ, Chang CW, Wu YC, et al: Selection
of DDX5 as a novel internal control for Q-RT-PCR from microarray
data using a block bootstrap re-sampling scheme. BMC Genomics.
8:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sanli T, Linher-Melville K, Tsakiridis T
and Singh G: Sestrin2 modulates AMPK subunit expression and its
response to ionizing radiation in breast cancer cells. PLoS One.
7:e320352012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim GT, Lee SH, Kim JI and Kim YM:
Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway
and induces apoptosis by increasing the generation of intracellular
ROS in a p53-independent manner. Int J Mol Med. 33:863–869.
2014.PubMed/NCBI
|
|
23
|
Au CW, Siu MK, Liao X, et al: Tyrosine
kinase B receptor and BDNF expression in ovarian cancers - Effect
on cell migration, angiogenesis and clinical outcome. Cancer Lett.
281:151–161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee DJ and Kang SW: Reactive oxygen
species and tumor metastasis. Mol Cells. 35:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa M: Reactive oxygen species in
tumor metastasis. Cancer Lett. 266:53–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu WS: The signaling mechanism of ROS in
tumor progression. Cancer Metastasis Rev. 25:695–705. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Waris G and Ahsan H: Reactive oxygen
species: role in the development of cancer and various chronic
conditions. J Carcinog. 5:142006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sotgia F, Martinez-Outschoorn UE and
Lisanti MP: Mitochondrial oxidative stress drives tumor progression
and metastasis: should we use antioxidants as a key component of
cancer treatment and prevention? BMC Med. 9:622011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reuter S, Gupta SC, Chaturvedi MM and
Aggarwal BB: Oxidative stress, inflammation, and cancer: how are
they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elsaleh H, Powell B, McCaul K, et al: P53
alteration and microsatellite instability have predictive value for
survival benefit from chemotherapy in stage III colorectal
carcinoma. Clin Cancer Res. 7:1343–1349. 2001.PubMed/NCBI
|
|
31
|
Zeng ZS, Sarkis AS, Zhang ZF, et al: p53
nuclear overexpression: an independent predictor of survival in
lymph node-positive colorectal cancer patients. J Clin Oncol.
12:2043–2050. 1994.PubMed/NCBI
|
|
32
|
Houbiers JG, van der Burg SH, van de
Watering LM, et al: Antibodies against p53 are associated with poor
prognosis of colorectal cancer. Br J Cancer. 72:637–641. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and
Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are
prognosis-related in colorectal cancer. World J Gastroenterol.
17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
|
